OCX · Oncocyte Corp - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $32.0K | - | $260.0K | $518.0K | $2.14M | - | $115.0K | $104.0K | $176.0K | - |
| Cost of Revenue | $17.0K | - | $121.0K | $168.0K | $806.0K | - | $43.0K | $32.0K | $252.0K | - |
| Gross Profit | $15.0K | - | $139.0K | $350.0K | $1.32M | - | $50.0K | $50.0K | ($98.0K) | - |
| R&D | $4.95M | - | $3.88M | $3.28M | $2.92M | - | $2.82M | $2.45M | $2.17M | - |
| SG&A | $2.99M | - | $2.54M | $2.65M | $3.12M | - | $2.56M | $2.41M | $2.67M | - |
| Total Operating Expenses | $4.43M | - | $11.19M | $10.19M | $8.12M | - | $13.56M | $4.68M | $9.17M | - |
| D&A | $631.0K | - | $340.0K | $326.0K | $335.0K | - | $318.0K | $304.0K | $313.0K | - |
| Operating Income | ($4.41M) | - | ($11.05M) | ($9.84M) | ($6.80M) | - | ($13.52M) | ($4.63M) | ($9.27M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $0 | - | $0 | $0 | $0 | - | - | - | - | - |
| Net Income | ($4.29M) | - | ($10.85M) | ($9.74M) | ($6.67M) | - | ($13.49M) | ($4.53M) | ($9.13M) | - |
| EPS - Basic | ($0.12) | - | ($0.34) | ($0.30) | ($0.26) | - | ($0.98) | ($0.36) | ($1.13) | - |
| EPS - Diluted | ($0.12) | - | ($0.34) | ($0.30) | ($0.26) | - | ($0.98) | ($0.36) | ($1.13) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $28.20M | $11.58M | $18.69M | $24.29M | $31.03M | $8.64M | $3.36M | $9.26M | $5.58M | $9.43M |
| Accounts Receivable | $157.0K | $1.13M | $258.0K | $512.0K | $3.54M | $1.61M | $209.0K | $85.0K | $161.0K | $484.0K |
| Inventory | $382.0K | $446.0K | $471.0K | $693.0K | $459.0K | $410.0K | $232.0K | - | - | - |
| Accounts Payable | $1.61M | $2.54M | $1.06M | $1.28M | $2.28M | $2.28M | $872.0K | $1.05M | $908.0K | $953.0K |
| Current Assets | $30.52M | $15.31M | $21.39M | $26.84M | $36.26M | $11.76M | $4.79M | $9.97M | $6.54M | $10.70M |
| Total Assets | $40.43M | $25.76M | $43.94M | $50.52M | $60.36M | $35.08M | $70.22M | $74.72M | $70.97M | $74.89M |
| Current Liabilities | $12.01M | $12.07M | $7.66M | $6.65M | $9.68M | $7.28M | $9.09M | $7.20M | $8.33M | $7.19M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $51.12M | $57.22M | $53.13M | $49.42M | $50.14M | $47.35M | $60.51M | $52.02M | $54.05M | $49.30M |
| Stockholders' Equity | ($10.69M) | ($31.46M) | ($9.20M) | $1.10M | $10.22M | ($12.27M) | $9.71M | $22.70M | $11.59M | $20.47M |
| Retained Earnings | ($405.05M) | ($400.76M) | ($377.81M) | ($366.95M) | ($357.21M) | ($350.54M) | ($317.03M) | ($303.54M) | ($299.00M) | ($289.88M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($7.64M) | - | - | - | ($5.86M) | - | - | - | ($3.83M) | - |
| Investing Cash Flow | ($613.0K) | - | - | - | ($307.0K) | - | - | - | ($24.0K) | - |
| Financing Cash Flow | $24.70M | - | - | - | $0 | - | - | - | - | - |
| CapEx | $613.0K | - | - | - | $307.0K | - | - | - | $24.0K | - |
| Free Cash Flow | ($8.25M) | - | - | - | ($6.17M) | - | - | - | ($3.85M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 46.9% | - | 53.5% | 67.6% | 62.0% | - | 43.5% | 48.1% | -55.7% | - |
| Operating margin | -13790.6% | - | -4249.2% | -1900.0% | -318.0% | - | -11752.2% | -4453.8% | -5265.3% | - |
| EBITDA margin | -11818.8% | - | -4118.5% | -1837.1% | -302.3% | - | -11475.7% | -4161.5% | -5087.5% | - |
| Net margin | -13406.3% | - | -4174.6% | -1880.7% | -312.0% | - | -11733.0% | -4355.8% | -5186.9% | - |
| Free cash flow margin | -25787.5% | - | - | - | -288.4% | - | - | - | -2189.8% | - |
| FCF / Net income | 1.92 | - | - | - | 0.92 | - | - | - | 0.42 | - |
| R&D / Revenue | 15478.1% | - | 1491.5% | 633.4% | 136.8% | - | 2449.6% | 2358.7% | 1232.4% | - |
| SG&A / Revenue | 9346.9% | - | 978.8% | 511.0% | 145.7% | - | 2230.4% | 2314.4% | 1518.8% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -10.6% | - | -24.7% | -19.3% | -11.1% | - | -19.2% | -6.1% | -12.9% | - |
| Return on equity | 40.1% | - | 118.0% | -887.2% | -65.3% | - | -138.9% | -20.0% | -78.8% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 2.54 | 1.27 | 2.79 | 4.04 | 3.75 | 1.62 | 0.53 | 1.38 | 0.78 | 1.49 |
| Quick ratio | 2.51 | 1.23 | 2.73 | 3.93 | 3.70 | 1.56 | 0.50 | 1.38 | 0.78 | 1.49 |
| Cash ratio | 2.35 | 0.96 | 2.44 | 3.65 | 3.20 | 1.19 | 0.37 | 1.29 | 0.67 | 1.31 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | -3.78 | -0.82 | -4.78 | 46.01 | 5.91 | -2.86 | 7.23 | 3.29 | 6.12 | 3.66 |
| Liabilities / Assets | 1.26 | 2.22 | 1.21 | 0.98 | 0.83 | 1.35 | 0.86 | 0.70 | 0.76 | 0.66 |
| Efficiency | ||||||||||
| Asset turnover | 0.00 | - | 0.01 | 0.01 | 0.04 | - | 0.00 | 0.00 | 0.00 | - |
| Inventory turnover | 0.04 | - | 0.26 | 0.24 | 1.76 | - | 0.19 | - | - | - |
| Days sales outstanding | 1791d | - | 362d | 361d | 604d | - | 663d | 298d | 334d | - |
| Days inventory outstanding | 8202d | - | 1421d | 1506d | 208d | - | 1969d | - | - | - |
| Days payable outstanding | 34675d | - | 3185d | 2774d | 1032d | - | 7402d | 11988d | 1315d | - |
| Cash conversion cycle | -24682d | - | -1402d | -908d | -220d | - | -4769d | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -98.5% | - | 126.1% | 398.1% | 1114.8% | - | -73.2% | -77.5% | -40.7% | - |
| Revenue CAGR (3y) | -52.4% | - | -36.5% | -37.0% | 14.5% | - | -51.1% | -62.9% | -46.1% | - |
| Revenue CAGR (5y) | -50.9% | - | -14.1% | 29.4% | 166.2% | - | - | - | - | - |
| Gross profit growth (YoY) | -98.9% | - | 178.0% | 600.0% | - | - | -79.8% | -81.6% | - | - |
| Operating income growth (YoY) | 35.1% | - | 18.3% | -112.5% | 26.6% | - | -107.5% | 44.2% | - | - |
| Net income growth (YoY) | 35.7% | - | 19.6% | -115.1% | 26.9% | - | -107.9% | 45.6% | - | - |
| EPS growth (YoY) | 53.8% | - | 65.3% | 16.7% | 77.0% | - | -21.0% | 66.4% | -927.3% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | -33.9% | - | - | - | -60.0% | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | -156.3% | - | -95.2% | -11.8% | - | -74.1% | -47.9% | -69.5% | -40.3% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$4.05M totalLaboratory Services$4.03M · 99.4%
Kitted Products$24.0K · 0.6%
Geographic
$4.05M totalUS$4.03M · 99.4%
Europe$24.0K · 0.6%
Peer comparison
Same SIC group: In Vitro & In Vivo Diagnostic Substances
Comparing Oncocyte Corp against the 5 most active filers in the same SIC group.